# A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers

> **NCT02512562** · PHASE1 · COMPLETED · sponsor: **Alios Biopharma Inc.** · enrollment: 32 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** AL-335
- **DRUG:** ACH-3102
- **DRUG:** Simeprevir

## Key facts

- **NCT ID:** NCT02512562
- **Lead sponsor:** Alios Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-31
- **Primary completion:** 2015-08-31
- **Final completion:** 2015-08-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02512562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02512562, "A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02512562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*